Transthyretin Amyloidosis (ATTR)

American College of Cardiology (ACC) 2025

Congress Details

March 29-31, 2025

Chicago, IL, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Congress Materials

Presentation Type

Poster

Location

Chicago, IL, USA

Title

Cardiac Function, Clinical Outcomes and Effect of Vutrisiran in Transthyretin Amyloid Cardiomyopathy - the HELIOS-B Trial

Sheikh-ACC-HB-maintenance_improvement-6MWT-KCCQ

Presentation Type

Poster

Location

Chicago, IL, USA

Title

Maintenance or Improvement of Functional Capacity, Health Status, and Quality of Life with Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy: Data from the HELIOS-B Study

Maurer_ACC-2025_HB-impact-of-HF-severity_poster

Presentation Type

Poster

Location

Chicago, IL, USA

Title

Impact of Baseline Heart Failure Severity on Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy in the HELIOS-B Trial: A Subgroup Analysis